type 2 diabetes mellitus
Conditions
Interventions
PET/MRI scan in patients with imeglimin
Sponsors
Kobe university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. type 2 diabetic patients 2. patients who have taken imeglimin for more than 1 month at the time of consent and are expected to take imeglimin until the date of PET/MRE examination 3.patients who have not taken metformin for more than 1 month at the time of consent and are not expected to take metformin until the date of PET/MRE examination 4. patients with no obvious lesions in the lower gastrointestinal tract 5. patients who are 20 years old or older at the time of consent 6. patients who have obtained written consent from the patient
Exclusion criteria
Exclusion criteria: 1. patients with the following contraindications to Buscopan (butyl scopolamine bromide) patients with hemorrhagic colitis patients with angle-closure glaucoma patients with dysuria due to prostatic hypertrophy patients with severe heart disease patients with anesthetic ileus patients with a history of hypersensitivity to this drug 2. patients with dementia or psychiatric disorders 3. patients with possible intestinal perforation or obstruction 4. patients with metals in the body that cannot be tested by PET/MRE 5. pregnant or lactating patients 6. other patients who are judged unsuitable for this study by theinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FDG excretion into the intestine per hour | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical parameters of blood biochemical test items such as HbA1c and blood glucose levels, and background factors of the research subjects (height, weight, gender, duration of diabetes, etc.) | — |
Countries
Japan
Contacts
Public ContactKazuhiko Sakaguchi
Kobe university Department of Diabetes and Endocrinology
Outcome results
None listed